A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across eight U.S. sites.

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help they'd normally find within lymph nodes — but on the go, within the tumor.

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

What major challenge of traditional CAR-T does the in vivo alleviate/address? In addi | Dr Adrian Bot, Capstan Therapeutics, ...